Dalton, R., Margalit, E., Mitchell, K., Millman, D., Zolanvari, M., Cavalcante, L. S. R., Tea, J. S., Antonio, D., Dhainaut, M., Delepine, C., Ovando, D., Fernandez, F., Salm, A., Hafner, A., Grossman, J. E., Chand, D. S., Alfa, R., Bear, D., Corse, E., Padrón, L. (2026). Artificial intelligence (AI) foundation model as a predictor of efficacy of next-generation checkpoint inhibition with botensilimab (BOT) + balstilimab (BAL) in solid tumors using pretreatment H&E images.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.2535